This announcement is not for release, publication or distribution in the United
States, Canada, Australia or Japan. This announcement is not an offer of
securities for sale in the United States or elsewhere.
Announcement no. 16/2007
To OMX the Nordic Exchange
Copenhagen, June 21, 2007
Good interest in subscribing for shares in Curalogic A/S
Following consultations with the Global Co-ordinator & Bookrunner, Danske
Markets (division of Danske Bank A/S) and the Co-Lead Manager, Piper Jaffray
Ltd., Curalogic has decided to complete the offering by issuing 18,000,000
shares of DKK 0.50 nominal value each and to set the offer price at DKK 17 per
share of DKK 0.50 nominal value each.
The offering of 18,000,000 shares of DKK 0.50 nominal value each in Curalogic
A/S (“Curalogic”) was met with good investor interest in Denmark as well as
abroad. Approximately 35% of the shares were subscribed by investors outside
Denmark.
Based on the offer price fixed and the share capital subscribed, the gross
proceeds from the offering amount to DKK 306 million.
Curalogic has granted to the Global Co-ordinator & Bookrunner and the Co-Lead
Manager an option for up to 30 days from the first day of trading to exercise
an over-allotment option for up to 2,000,000 shares of DKK 0.50 nominal value
each. If the over-allotment option is exercised in full, the offering will
amount to a total of 20,000,000 shares of DKK 0.50 nominal value each.
Allocation of shares
As the demand exceeds the number of offered shares, a reduction in applications
received has been made.
Allocation of shares for applications for more than DKK 2 million was made on
an individual basis.
Allocation of shares for applications up to and including DKK 2 million was
made as follows:
• Applications up to and including 5,900 shares: full allocation.
• Applications for more than 5,900 shares: are allocated 5,900 shares and 35%
of the remaining application rounded to the nearest whole number of shares.
Timetable
First day of trading in the temporary securities identification code
(DK0060085264) June 25, 2007
Payment for the offer shares June 26, 2007
It is expected that the temporary securities identification code of the offer
shares will be merged with the securities identification code of the existing
shares as soon as possible after registration of the capital increase with the
Danish Commerce and Companies Agency.
Stabilisation
Danske Markets acts as stabilisation agent. Stabilisation activities with a
view to supporting the market price of the shares may commence on June 25, 2007
and continue for a period of up to 30 days after June 25, 2007. Any such
stabilisation measures may, if commenced, be discontinued at any time without
prior notice and will in any event cease 30 days after June 25, 2007.
Following the completion of the offering, the company's CEO, Peter Moldt, said:
"We are very pleased with the positive response that we have received from
investors in this transaction. We are also pleased about the many new investors
we have received in the company which has given us the opportunity to broaden
our shareholder base and the possibility to put more weight on international
investors. We now look forward to honouring the confidence by initiating our
efforts to bringing the ragweed product towards a European registration
application in 2008 and to accelerate the development of our grass product."
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange Copenhagen (CUR.CO). Curalogic develops innovative pharmaceuticals for
the treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of
allergy treatment, and make it the preferred type of allergy treatment among
patients. Curalogic has a broad and mature pipeline with a product for
treatment of ragweed allergy in Phase III, a product for treatment of grass
allergy ready for Phase III, a product for treatment of cat allergy in Phase II
and a product for treatment of house dust mite allergy preparing for clinical
trials.
DISCLAIMER
It may be unlawful to distribute this announcement in certain jurisdictions.
This announcement is not for distribution in the United States, Canada,
Australia or Japan. The information in this announcement does not constitute an
offer of securities for sale in the United States, Canada, Australia or Japan.
The Company does not intend to register securities in the United States or to
conduct a public offering of securities in the United States. Securities may
not be offered or sold in the United States unless they are registered or are
exempt from registration.
